These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34260934)

  • 1. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.
    Huang H; Gont A; Kee L; Dries R; Pfeifer K; Sharma B; Debruyne DN; Harlow M; Sengupta S; Guan J; Yeung CM; Wang W; Hallberg B; Palmer RH; Irwin MS; George RE
    Cell Rep; 2021 Jul; 36(2):109363. PubMed ID: 34260934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for ligand reception by anaplastic lymphoma kinase.
    Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
    Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
    Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
    Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ALK receptor in sympathetic neuron development and neuroblastoma.
    Janoueix-Lerosey I; Lopez-Delisle L; Delattre O; Rohrer H
    Cell Tissue Res; 2018 May; 372(2):325-337. PubMed ID: 29374774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
    Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
    Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth.
    Lai WY; Chuang TP; Borenäs M; Lind DE; Hallberg B; Palmer RH
    Cell Death Differ; 2024 Jul; 31(7):910-923. PubMed ID: 38858548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.
    Di Paolo D; Ambrogio C; Pastorino F; Brignole C; Martinengo C; Carosio R; Loi M; Pagnan G; Emionite L; Cilli M; Ribatti D; Allen TM; Chiarle R; Ponzoni M; Perri P
    Mol Ther; 2011 Dec; 19(12):2201-12. PubMed ID: 21829174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.
    Ota Y; Yoda H; Inoue T; Watanabe T; Shinozaki Y; Takatori A; Nagase H
    PLoS One; 2021; 16(9):e0257718. PubMed ID: 34591871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
    He MY; Li WK; Zheng QC; Zhang HX
    ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.
    Pucci P; Lee LC; Han M; Matthews JD; Jahangiri L; Schlederer M; Manners E; Sorby-Adams A; Kaggie J; Trigg RM; Steel C; Hare L; James ER; Prokoph N; Ducray SP; Merkel O; Rifatbegovic F; Luo J; Taschner-Mandl S; Kenner L; Burke GAA; Turner SD
    Nat Commun; 2024 Apr; 15(1):3422. PubMed ID: 38653965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.
    Satoh S; Takatori A; Ogura A; Kohashi K; Souzaki R; Kinoshita Y; Taguchi T; Hossain MS; Ohira M; Nakamura Y; Nakagawara A
    Sci Rep; 2016 Sep; 6():32682. PubMed ID: 27604320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
    Wulf AM; Moreno MM; Paka C; Rampasekova A; Liu KJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
    Szydzik J; Lind DE; Arefin B; Kurhe Y; Umapathy G; Siaw JT; Claeys A; Gabre JL; Van den Eynden J; Hallberg B; Palmer RH
    Nat Commun; 2021 Nov; 12(1):6813. PubMed ID: 34819497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ALK as a major familial neuroblastoma predisposition gene.
    Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
    Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
    Hagiwara K; Tokunaga T; Iida H; Nagai H
    Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
    Mus LM; Lambertz I; Claeys S; Kumps C; Van Loocke W; Van Neste C; Umapathy G; Vaapil M; Bartenhagen C; Laureys G; De Wever O; Bexell D; Fischer M; Hallberg B; Schulte J; De Wilde B; Durinck K; Denecker G; De Preter K; Speleman F
    Sci Rep; 2020 Jan; 10(1):218. PubMed ID: 31937834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.
    Uçkun E; Siaw JT; Guan J; Anthonydhason V; Fuchs J; Wolfstetter G; Hallberg B; Palmer RH
    J Mol Biol; 2021 Sep; 433(19):167158. PubMed ID: 34273398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
    PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.